Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Kenneth W. Mahaffey, Meg Jardine et al.|New England Journal of Medicine|2019Cited by 6k
Dapagliflozin in Patients with Chronic Kidney DiseaseHiddo J.L. Heerspink, David C. Wheeler, Bergur V. Stefánsson et al.|New England Journal of Medicine|2020Cited by 5.2k
Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global OutcomesAndrew S. Levey, Garabed Eknoyan, R. C. Atkins et al.|Kidney International|2007Cited by 1.5k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsColin Baigent, Faı̈ez Zannad, Martin Landray et al.|The Lancet|2022Cited by 969
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policyAdeera Levin, Robert G. Nelson, Chih-Wei Yang et al.|The Lancet|2017Cited by 923